Literature DB >> 9629335

Treatment of febrile seizures with intermittent clobazam.

M L Manreza1, J L Gherpelli, L R Machado-Haertel, C C Pedreira, C O Heise, A Diament.   

Abstract

Fifty children, 24 female and 26 male, with ages varying from 6 to 72 months (mean = 23.7 m.) that experienced at least one febrile seizure (FS) entered a prospective study of intermittent therapy with clobazam. Cases with severe neurological abnormalities, progressive neurological disease, afebrile seizures, symptomatic seizures of other nature, or seizures during a central nervous system infection were excluded. Seizures were of the simple type in 25 patients, complex in 20 and unclassified in 5. The mean follow-up period was 7.9 months (range = 1 to 23 m.), and the age at the first seizure varied from 5 to 42 months (mean = 16.8 m.). Clobazam was administered orally during the febrile episode according to the child's weight: up to 5 kg, 5 mg/day; from 5 to 10 kg, 10 mg/day; from 11 to 15 kg, 15 mg/day, and over 15 kg, 20 mg/day. There were 219 febrile episodes, with temperature above 37.8 degrees C, in 40 children during the study period. Twelve children never received clobazam and 28 received the drug at least once. Drug efficacy was measured by comparing FS recurrence in the febrile episodes that were treated with clobazam with those in which only antipyretic measures were taken. Ten children (20%) experienced a FS during the study period. Of the 171 febrile episodes treated with clobazam there were only 3 recurrences (1.7%), while of the 48 episodes treated only with antipyretic measures there were 11 recurrences (22.9%), a difference highly significant (p < 0.0001). Adverse effects occurred in 10/28 patients (35.7%), consisting mainly in vomiting, somnolence and hyperactivity. Only one patient had recurrent vomiting which lead to drug interruption. These effects did not necessarily occurred in every instance the drug was administered, being present in one febrile episode and not in the others. We conclude that clonazepam is safe and efficacious in preventing FS recurrence. It may be an alternative to diazepam in the intermittent treatment of FS recurrence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9629335     DOI: 10.1590/s0004-282x1997000500012

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  3 in total

1.  Diazepam versus clobazam for intermittent prophylaxis of febrile seizures.

Authors:  Nahid Khosroshahi; Fatemeh Faramarzi; Payman Salamati; Seeid Mohammad Ogaghi Haghighi; Kamyar Kamrani
Journal:  Indian J Pediatr       Date:  2010-10-02       Impact factor: 1.967

2.  Intermittent clobazam therapy in febrile seizures.

Authors:  Winsley Rose; Chellam Kirubakaran; Julius Xavier Scott
Journal:  Indian J Pediatr       Date:  2005-01       Impact factor: 1.967

3.  Febrile seizures: four steps algorithmic clinical approach.

Authors:  Mahmoud Mohammadi
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.